Τίτλος:
The role of inflammation in diabetes: Current concepts and future perspectives
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Diabetes is a complex metabolic disorder affecting the glucose status of the human body. Chronic hyperglycaemia related to diabetes is associated with end organ failure. The clinical relationship between diabetes and atherosclerotic cardiovascular disease is well established. This makes therapeutic approaches that simultaneously target diabetes and atherosclerotic disease an attractive area for research. The majority of people with diabetes fall into two broad pathogenetic categories, type 1 or type 2 diabetes. The role of obesity, adipose tissue, gut microbiota and pancreatic beta cell function in diabetes are under intensive scrutiny with several clinical trials to have been completed while more are in development. The emerging role of inflammation in both type 1 and type 2 diabetes (T1D and T1D) pathophysiology and associated metabolic disorders, has generated increasing interest in targeting inflammation to improve prevention and control of the disease. After an extensive review of the possible mechanisms that drive the metabolic pattern in T1D and T2D and the inflammatory pathways that are involved, it becomes ever clearer that future research should focus on a model of combined suppression for various inflammatory response pathways. © RADCLIFFE CARDIOLOGY 2019.
Συγγραφείς:
Tsalamandris, S.
Antonopoulos, A.S.
Oikonomou, E.
Papamikroulis, G.-A.
Vogiatzi, G.
Papaioannou, S.
Deftereos, S.
Tousoulis, D.
Περιοδικό:
European Cardiology Review
Εκδότης:
Radcliffe Cardiology
Λέξεις-κλειδιά:
alfacalcidol; alpha 1 antitrypsin; anakinra; antidiabetic agent; antiinflammatory agent; bht 3021; biological marker; biological product; butylcresol; calcitriol; canakinumab; cytokine; diacerein; etanercept; gevokizumab; HLA DR4 antigen; infliximab; interleukin 1beta; interleukin 6; lenercept; methotrexate; otelixizumab; rituximab; salicylate sodium; salsalate; sialic acid; teplizumab; tumor necrosis factor; tumor necrosis factor antibody; unindexed drug; vitamin D, adipose tissue; antidiabetic activity; antiinflammatory activity; atherosclerosis; bariatric surgery; cardiovascular disease; clinical trial (topic); coronary artery atherosclerosis; diabetes mellitus; diet supplementation; disease association; drug mechanism; drug megadose; drug targeting; dyslipidemia; glucosuria; human; hyperglycemia; immune system; inflammation; insulin dependent diabetes mellitus; insulin release; insulin resistance; intestine flora; low drug dose; metabolic disorder; metabolic syndrome X; non insulin dependent diabetes mellitus; nonhuman; obesity; pancreas islet beta cell; pathophysiology; Review; thrombosis
DOI:
10.15420/ecr.2018.33.1
